drugset / Trial / NCT01031420

Dose Dense MVAC for Muscle Invasive Bladder Cancer

NCT01031420

Phase 2 Completed 54 enrolled Fox Chase Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

Standard treatment for early stage bladder cancer is chemotherapy with methotrexate (M), vinblastine (V), adriamycin (A), and cisplatin (C) followed by surgical removal of any remaining cancer and the bladder with the intent of cure. The M V chemotherapy is usually given every 14 days with the AC given along each 28 days. This study looks at giving the same drugs at the same doses closer together, all drugs every 14 days, with the support of growth factor medication to promote growth of the white blood cells and platelets and allow chemotherapy to be finished sooner and surgery to be done sooner.

Timeline

Start
2009-12-07
Primary completion
2013-07-19
Completion
2013-08-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 70 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 30 mg/m2 Intravenous
Subject Methotrexate Small molecule 30 mg/m2 Intravenous
Subject Vinblastine Small molecule 3 mg/m2 Intravenous